Active Biotech AB (publ) (STO:ACTI)

Market Cap	273.10M
Revenue (ttm)	n/a
Net Income (ttm)	-39.90M
Shares Out	1.23B
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,755,913
Average Volume	12,874,901
Open	0.2240
Previous Close	0.2220
Day's Range	0.2030 - 0.2240
52-Week Range	0.0630 - 0.5170
Beta	1.47
RSI	55.09
Earnings Date	Aug 21, 2025

About Active Biotech AB

Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as non-infectious uveitis; Tasquinimod, an orally active small molecule immunomodulator that blocks tumor-promoting signals in the bone marrow microenvir...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1983
• Employees: 6
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ACTI